CY1114733T1 - Παραγοντες απεικονισης που στοχευουν βιταμινες - Google Patents

Παραγοντες απεικονισης που στοχευουν βιταμινες

Info

Publication number
CY1114733T1
CY1114733T1 CY20131101164T CY131101164T CY1114733T1 CY 1114733 T1 CY1114733 T1 CY 1114733T1 CY 20131101164 T CY20131101164 T CY 20131101164T CY 131101164 T CY131101164 T CY 131101164T CY 1114733 T1 CY1114733 T1 CY 1114733T1
Authority
CY
Cyprus
Prior art keywords
vitamins
imaging agents
agents targeting
targeting
compound
Prior art date
Application number
CY20131101164T
Other languages
Greek (el)
English (en)
Inventor
Matthew A Parker
Christopher Paul Leamon
Original Assignee
Endocyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte, Inc. filed Critical Endocyte, Inc.
Publication of CY1114733T1 publication Critical patent/CY1114733T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CY20131101164T 2002-05-06 2013-12-27 Παραγοντες απεικονισης που στοχευουν βιταμινες CY1114733T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37857102P 2002-05-06 2002-05-06
EP09171503.7A EP2151250B1 (en) 2002-05-06 2003-05-06 Vitamin-Targeted imaging agents

Publications (1)

Publication Number Publication Date
CY1114733T1 true CY1114733T1 (el) 2016-12-14

Family

ID=29401611

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101164T CY1114733T1 (el) 2002-05-06 2013-12-27 Παραγοντες απεικονισης που στοχευουν βιταμινες

Country Status (18)

Country Link
US (5) US7128893B2 (cg-RX-API-DMAC7.html)
EP (4) EP2258401B1 (cg-RX-API-DMAC7.html)
JP (1) JP4801348B2 (cg-RX-API-DMAC7.html)
KR (1) KR100978418B1 (cg-RX-API-DMAC7.html)
CN (2) CN101648028B (cg-RX-API-DMAC7.html)
AT (1) ATE448799T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003239383C1 (cg-RX-API-DMAC7.html)
CA (1) CA2484345C (cg-RX-API-DMAC7.html)
CY (1) CY1114733T1 (cg-RX-API-DMAC7.html)
DE (1) DE60330135D1 (cg-RX-API-DMAC7.html)
DK (3) DK2258401T3 (cg-RX-API-DMAC7.html)
ES (4) ES2500922T3 (cg-RX-API-DMAC7.html)
IL (1) IL164811A (cg-RX-API-DMAC7.html)
NZ (1) NZ536467A (cg-RX-API-DMAC7.html)
PT (2) PT2151250E (cg-RX-API-DMAC7.html)
SI (2) SI2260875T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003092742A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408664B (cg-RX-API-DMAC7.html)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
MXPA03010035A (es) * 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
DK2258401T3 (da) 2002-05-06 2014-10-13 Endocyte Inc Folat-receptor targetede billeddannelsesmidler
DE60326833D1 (de) * 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CA2524441C (en) * 2003-05-06 2012-03-20 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor
JP4680185B2 (ja) 2003-05-30 2011-05-11 パーデュー・リサーチ・ファウンデーション アテローム性動脈硬化症の診断法
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7977500B2 (en) * 2004-11-10 2011-07-12 University Of South Florida Platinum complexes for targeted drug delivery
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2604283A1 (en) * 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN101646639A (zh) 2007-04-11 2010-02-10 默克阿泼洛发股份公司 18f-标记的叶酸
KR101605426B1 (ko) * 2007-04-11 2016-03-22 메르크 앤드 씨에 진단 이미징 및 방사선치료에 사용하기 위한 폴레이트-컨쥬게이트 및 대응하는 금속-킬레이트 착물
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
EP2222328A4 (en) * 2007-11-15 2013-06-05 Endocyte Inc PROCESS FOR THE ADMINISTRATION OF CONJUGATES
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US8426398B2 (en) 2009-01-13 2013-04-23 Emory University Conjugates of noscapine and folic acid and their use in treating cancer
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
CA2754492A1 (en) * 2009-03-05 2010-09-10 Purdue Research Foundation Method for early imaging of atherosclerosis
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
HRP20151294T1 (hr) 2010-04-05 2016-03-11 Prognosys Biosciences, Inc. Biološka testiranja sa prostornim kodiranjem
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
KR102036199B1 (ko) 2011-08-17 2019-10-24 메르크 앤드 씨에 알부민-결합 개체들의 폴레이트 공액체들
US9884123B2 (en) 2012-01-03 2018-02-06 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20150174273A1 (en) * 2012-07-25 2015-06-25 Emory University Imaging and therapeutic methods for treating parathyroid tumors
IN2015DN04147A (cg-RX-API-DMAC7.html) 2012-10-16 2015-10-16 Endocyte Inc
EP2909337B1 (en) 2012-10-17 2019-01-09 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
KR101551232B1 (ko) 2012-10-26 2015-09-10 한국원자력연구원 Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
WO2014150943A1 (en) * 2013-03-15 2014-09-25 Purdue Research Foundation Asthma imaging and therapy
WO2014210223A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287731A1 (en) * 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EP3071971B1 (en) 2013-11-19 2019-04-24 Purdue Research Foundation Patient selection method for inflammation
KR20160132496A (ko) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. 초분자 조합 치료제
EP3160514B1 (en) 2014-06-27 2024-07-31 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
US20160166679A1 (en) * 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016111834A1 (en) 2015-01-09 2016-07-14 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
ES2955488T3 (es) 2015-04-10 2023-12-01 Spatial Transcriptomics Ab Análisis multiplex de especímenes biológicos de ácidos nucleicos espacialmente distinguidos
WO2017015109A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3334466B1 (en) 2015-08-14 2020-05-13 Endocyte, Inc. Method of imaging with a chelating compound
KR102723865B1 (ko) 2015-12-04 2024-10-29 10엑스 제노믹스, 인크. 핵산 분석을 위한 방법 및 조성물
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
CA3017214A1 (en) * 2016-03-16 2017-09-21 Purdue Research Foundation Carbonic anhydrase ix targeting agents and methods
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
ES3025461T3 (en) 2017-08-22 2025-06-09 Purdue Research Foundation Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
JP2021522193A (ja) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 癌を治療する方法
AU2019266207B2 (en) 2018-05-07 2025-04-24 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
CA3114396A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
EP3969052A1 (en) 2019-05-17 2022-03-23 Alnylam Pharmaceuticals Inc. Oral delivery of oligonucleotides
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
WO2021086982A2 (en) 2019-10-28 2021-05-06 Beckman Coulter, Inc. Compounds for the identification of microbial classes and uses thereof
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
CA3160329A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
IL313194A (en) 2020-10-30 2024-07-01 Tod SPEER Oligonucleotide-based treatments and their uses
US20240343746A1 (en) 2020-12-31 2024-10-17 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
US20240336914A1 (en) 2020-12-31 2024-10-10 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
US20240165250A1 (en) * 2021-01-08 2024-05-23 Lycia Therapeutics, Inc. Bifunctional Folate Receptor Binding Compounds
WO2022256503A1 (en) 2021-06-03 2022-12-08 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
JP2024527584A (ja) 2021-07-09 2024-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
CA3226269A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
JP2024526890A (ja) 2021-07-21 2024-07-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド 代謝障害関連標的遺伝子ｉｒｎａ組成物およびその使用方法
KR20240101590A9 (ko) 2021-10-15 2025-12-10 알닐람 파마슈티칼스 인코포레이티드 간외 전달 irna 조성물 및 이를 이용하는 방법
JP2025516680A (ja) 2022-05-13 2025-05-30 アルナイラム ファーマシューティカルズ， インコーポレイテッド 一本鎖ループオリゴヌクレオチド
JP2025522880A (ja) 2022-06-30 2025-07-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
CA2101942C (en) 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6022966A (en) 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
DE4311022C2 (de) * 1993-03-31 1996-07-11 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4310999C2 (de) * 1993-03-31 1996-07-18 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
DE4311023C2 (de) * 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4425781A1 (de) * 1994-07-14 1996-01-18 Schering Ag Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel
US6083480A (en) * 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
MXPA03010035A (es) 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
DK2258401T3 (da) * 2002-05-06 2014-10-13 Endocyte Inc Folat-receptor targetede billeddannelsesmidler
EP2517729A3 (en) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CA2524441C (en) * 2003-05-06 2012-03-20 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor

Also Published As

Publication number Publication date
EP2258401A3 (en) 2011-08-24
WO2003092742A1 (en) 2003-11-13
CN101648028A (zh) 2010-02-17
KR100978418B1 (ko) 2010-08-26
JP4801786B2 (ja) 2011-10-26
AU2003239383A1 (en) 2003-11-17
US8313728B2 (en) 2012-11-20
SI2151250T1 (sl) 2014-02-28
EP1501551B1 (en) 2009-11-18
US20130237687A1 (en) 2013-09-12
ES2472423T3 (es) 2014-07-01
US20040033195A1 (en) 2004-02-19
AU2003239383B2 (en) 2008-10-16
CN1662263A (zh) 2005-08-31
ES2336780T3 (es) 2010-04-16
DK2260875T3 (da) 2014-06-30
EP2260875B1 (en) 2014-04-23
EP2260875A3 (en) 2011-08-24
JP2011012066A (ja) 2011-01-20
SI2260875T1 (sl) 2014-07-31
EP2258401B1 (en) 2014-07-09
US7862798B2 (en) 2011-01-04
US8865126B2 (en) 2014-10-21
HK1141440A1 (en) 2010-11-12
JP2006501149A (ja) 2006-01-12
US20140065068A1 (en) 2014-03-06
CA2484345A1 (en) 2003-11-13
DE60330135D1 (de) 2009-12-31
CN100528241C (zh) 2009-08-19
CA2484345C (en) 2015-09-29
NZ536467A (en) 2006-11-30
ES2500922T3 (es) 2014-10-01
PT2151250E (pt) 2013-12-09
US20070031334A1 (en) 2007-02-08
US7128893B2 (en) 2006-10-31
CN101648028B (zh) 2012-11-21
EP1501551A4 (en) 2006-01-11
ZA200408664B (en) 2007-04-25
EP2151250B1 (en) 2013-10-02
PT2260875E (pt) 2014-06-25
US8834842B2 (en) 2014-09-16
IL164811A (en) 2012-06-28
DK2151250T3 (da) 2013-12-16
EP1501551A1 (en) 2005-02-02
ATE448799T1 (de) 2009-12-15
ES2438008T3 (es) 2014-01-15
EP2260875A2 (en) 2010-12-15
JP4801348B2 (ja) 2011-10-26
US20090324499A1 (en) 2009-12-31
AU2003239383C1 (en) 2009-03-19
DK2258401T3 (da) 2014-10-13
EP2151250A1 (en) 2010-02-10
EP2258401A2 (en) 2010-12-08
KR20040104686A (ko) 2004-12-10

Similar Documents

Publication Publication Date Title
CY1114733T1 (el) Παραγοντες απεικονισης που στοχευουν βιταμινες
BR0307924A (pt) N-aril-2-oxazolidinona-5-carboxamidas e seus derivados
DZ3420A1 (fr) Combinaison d'herbicides avec des sulfonylurees speciales
DE69907977D1 (de) Pyrrolobenzodiazepine
DE60112974D1 (en) Carbolinderivate
PA8561801A1 (es) Cis-imidazolinas
EP1572639A4 (en) ON INTEGRIN TARGET MEDIUM FOR IMAGE PRESENTATION
DK1385514T5 (da) Spiroinden- og spiroindanforbindelser
DE60215179D1 (de) Dolastatin 10 derivate
DE60222044D1 (de) Nitrid-Feldeffekttransistor
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DK1414828T3 (da) Antitumoranaloger
DE60216233D1 (en) Carbolinderivate
ITMI20011306A0 (it) Poliuretani vulcanizzabili
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
ATE321760T1 (de) N-aryl-2-oxazolidinone und deren derivate
BRPI0413744A (pt) n-aril-2-ciano-oxazolidinonas e seus derivados
BRPI0409143A (pt) n-aril-2-oxazolidinona-5-carboxamidas e seus derivados
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
ATE377608T1 (de) Hemoglobin konjugate
ATE478155T1 (de) Glycopeptidantibiotika
ES1048879Y (es) Accesorio vertical de sulfatado sobre tractor.
UY28151A1 (es) Derivados de 1,2,4-triaminobenceno
ATE295117T1 (de) Medizinische bandelektrode
UA6121S (uk) Емблема «джерело»